Evidence map›Paper›PMID 41778053›Full record

ArticleMediators of inflammation2026

The TWEAK-HOIP-HuR Axis: A Novel Mechanism of AMPK Inactivation and Metabolic Reprogramming in Lupus Nephritis Mesangial Cells Hyperproliferation.

Zongnan Ding, Enzhuo Liu, Xinyue Li, Yujie Zhang, Lei Li, Chenghua Weng, Zhiqin Liu, Zhichun Liu

Abstract read
In one paragraph

Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zongnan DingDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, China, suda.edu.cn.ORCID https://orcid.org/0009-0001-4652-1616
Enzhuo LiuDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, China, suda.edu.cn.ORCID https://orcid.org/0009-0009-1030-0182
Xinyue LiDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, China, suda.edu.cn.ORCID https://orcid.org/0009-0000-4262-1444
Yujie ZhangDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, China, suda.edu.cn.ORCID https://orcid.org/0009-0008-2261-1685
Lei LiDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, China, suda.edu.cn.ORCID https://orcid.org/0009-0006-8521-990X
Chenghua WengDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, China, suda.edu.cn.ORCID https://orcid.org/0000-0001-7253-7745
Zhiqin LiuThe College of Food Science and Biology, Hebei University of Science and Technology, Shijiazhuang, China, hebust.edu.cn.ORCID https://orcid.org/0009-0004-9257-8690
Zhichun LiuDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, China, suda.edu.cn.ORCID https://orcid.org/0000-0001-6170-9601

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cellular proliferation is intrinsically coupled to metabolic reprogramming, a conserved biological association that modulates the progression of diverse proliferative pathologies. In the present study, we unveil a novel mechanistic link between tumor necrosis factor-like weak inducer of apoptosis (TWEAK) signaling and Human antigen R (HuR)-driven metabolic alterations in lupus nephritis (LN), a progressive renal disorder characterized by mesangial cells (MCs) hyperproliferation and glomerular dysfunction. We demonstrate that TWEAK stimulation elicits linear ubiquitination of AMP-activated protein kinase (AMPK)-a master regulator of cellular energy metabolism-mediated by the E3 ubiquitin ligase HOIL-1-interacting protein (HOIP). This posttranslational modification directly results in the functional inactivation of AMPK. Notably, suppressed AMPK activity drives the nuclear export of HuR, a ubiquitously expressed RNA-binding protein, leading to its subsequent accumulation in the cytoplasmic compartment. In the cytosol, HuR selectively binds to and stabilizes the mRNAs of key cell cycle regulators, with Cyclin D1 being a primary target. This stabilization of Cyclin D1 mRNA ultimately promotes aberrant MCs proliferation, a pathological hallmark of LN. To validate the functional relevance of the pathogenesis, we performed HOIP knockdown experiments in MCs. Consistent with our mechanistic model, HOIP depletion significantly restored AMPK phosphorylation (a well-established surrogate marker of AMPK activation), suppressed HuR cytoplasmic shuttling, reduced Cyclin D1 expression at both the transcriptional and translational levels, and ultimately inhibited aberrant MCs proliferation in vitro. Collectively, our results establish the TWEAK-HOIP-AMPK-HuR axis as a critical signaling axis that couples metabolic dysfunction to dysregulated cell cycle progression in LN. This work not only provides critical new mechanistic insights into the pathogenesis of mesangial hyperproliferation in LN but also highlights potential therapeutic targets, including HOIP and cytoplasmic HuR, for the development of targeted treatments for LN and other renal diseases characterized by abnormal MCs proliferation.

Indexed as

AMP-Activated Protein KinasesCytokine TWEAKELAV-Like Protein 1Lupus NephritisMesangial CellsUbiquitin-Protein LigasesCell ProliferationHumansSignal TransductionTumor Necrosis FactorsAMP-Activated Protein KinasesCytokine TWEAKELAV-Like Protein 1TNFSF12 protein, humanTumor Necrosis FactorsUbiquitin-Protein Ligases

Identifiers

PMID41778053
PMCPMC12951119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.